Carumonam(CRMN)是日本武田制药公司,首次从细菌中发现的单环β-内酰胺抗生素Sulfazecin,为骨架进行化学改造而得到的新的注射用抗生素,结构如附图。该单环β-内酰胺类抗生素,为区别于青霉素类和头孢烯类,被命名为monobactan类抗生素,其中之一还有Aztreonam(AZT)。 CRMN对包括绿脓杆菌在内的革蓝氏阴性菌的抗菌活力,比已有的β-内酰胺类注射剂强,而且其安全性已由毒性试验、一般药理试验、Ⅰ期临床所证实。为用于临床,日 Carumonam (CRMN) is a new injectable antibiotic made by Japan Takeda Pharmaceutical Co., Ltd., a monocyclic β-lactam antibiotic Sulfazecin which is first discovered from bacteria. Its structure is shown in the attached figure. This monocyclic beta-lactam antibiotic, which is distinguished from penicillins and cephem, is named monobactan antibiotic, and one of them is Aztreonam (AZT). The antibacterial activity of CRMN against Gram-negative bacteria, including Pseudomonas aeruginosa, is stronger than the existing β-lactam injections and its safety has been confirmed by toxicity tests, general pharmacological tests and phase I clinical trials. For clinical, day